Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | MTOR | P42345 | 3/20 | 0.69 |
| ▸ | GMNN | O75496 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 5/20 | 0.67 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.67 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.67 |
| ▸ | HTR2B | P41595 | 4/20 | 0.67 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10735604 | 0.85 | GRIN2B (0.64) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL6254237 | 0.83 | GMNN (1.00) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| SCHEMBL11055006 | 0.83 | GRIN2B (0.80) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL154047 | 0.83 | GMNN (1.00) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL7517402 | 0.83 | GMNN (1.00) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL7525726 | 0.82 | GMNN (0.98) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL7212849 | 0.82 | GMNN (0.98) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| Eliprodil SCHEMBL7521721 | 0.82 | GMNN (0.98) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| (R,S)-Ifenprodil SCHEMBL12618846 | 0.82 | GRIN2B (1.00) | GRIN2BGRIN1CYP3A4MTORGMNN | |
| (R,S)-Ifenprodil SCHEMBL21614195 | 0.82 | GRIN2B (1.00) | GRIN2BGRIN1CYP3A4MTORGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207284-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | SOLENO THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210322434-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | SOLENO THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-11045478-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10874676-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | Essentials, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200237772-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20200222417-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3217963-B1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | ESSENTIALIS INC (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200147100-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | SOLENO THERAPEUTICS, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10456408-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | ESSENTIALIS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2006026469-A2 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2004075832-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN USING DHEA AND DERIVATIVES THEREOF | LUCAS JOHN M (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20030133951-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| EP-0939635-A1 | IMPROVED INTRAOCULAR IRRIGATING SOLUTION CONTAINING A POLYAMINE ANTAGONIST | ALCON LABORATORIES, INC. (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0854719-A1 | USE OF POLYAMINE ANTAGONISTS FOR THE TREATMENT OF GLAUCOMA | SYNTHELABO (FR) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998019678-A1 | IMPROVED INTRAOCULAR IRRIGATING SOLUTION CONTAINING A POLYAMINE ANTAGONIST | ALCON LABORATORIES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1997002823-A1 | USE OF POLYAMINE ANTAGONISTS FOR THE TREATMENT OF GLAUCOMA | SYNTHELABO (FR) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874676-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | KCNJ1, KCNJ11, KCNN1 | GRIN2B 1284/4885GRIN1 1313/4885CYP3A4 3202/4885 |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | GRIN2B 1627/4885GRIN1 1630/4885CYP3A4 333/4885 |
| US-20200222417-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | GRIN2B 1627/4885GRIN1 1630/4885CYP3A4 333/4885 |
| US-20210322434-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | KCNJ1, KCNJ11, KCNN1 | GRIN2B 1284/4885GRIN1 1313/4885CYP3A4 3202/4885 |
| US-20240207284-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | KCNJ1, KCNJ11, KCNN1 | GRIN2B 1284/4885GRIN1 1313/4885CYP3A4 3202/4885 |
| US-10456408-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | KCNJ1, KCNJ11, KCNN1 | GRIN2B 1284/4885GRIN1 1313/4885CYP3A4 3202/4885 |
| US-20200237772-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | GRIN2B 2379/4885GRIN1 2346/4885CYP3A4 302/4885 |
| US-20200147100-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | KCNJ1, KCNJ11, KCNN1 | GRIN2B 1284/4885GRIN1 1313/4885CYP3A4 3202/4885 |
| US-11045478-B2 | Salts of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ2 | GRIN2B 1627/4885GRIN1 1630/4885CYP3A4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.